A little known side effect with a huge impact
Vitamins By Condition
Learn about User Reviews and read IMPORTANT information about user generated content
Conditions of Use and Important Information: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.
Dr. Reddy's Launches Toripalimab In India For Nasopharyngeal Carcinoma Treatment
Toripalimab launched in India for metastatic and recurrent nasopharyngeal carcinoma, offering new hope for patients with this rare and aggressive cancer. Dr. Reddy's Laboratories announced the introduction of Toripalimab in India for the treatment of adults with Nasopharyngeal carcinoma (NPC), a rare and aggressive head and neck cancer that develops in the nasopharynx, the upper section of the throat (1✔ ✔Trusted SourceDr. Reddy's launches Toripalimab in India to treat rare form of head & neck cancerGo to source). 'Did You Know?Nearly 9 in 10 (88%) of all oral cancer cases caused by smokeless tobacco and areca nut use. #medindia #oralcancer #cancer'
Advertisement
Mechanism of Action of Toripalimab Toripalimab is an anti-PD-1 monoclonal antibody that works by inhibiting PD-1 interactions with its ligands, PD-L1 and PD-L2, thereby enhancing the internalization (endocytosis) of the receptor. By blocking these interactions, it enables the immune system to target and destroy tumor cells. When combined with standard chemotherapy, Toripalimab has demonstrated a 48% reduction in the risk of disease progression or death.Advertisement
Significance of Toripalimab's Launch in India "The launch of Toripalimab is a significant milestone for patients diagnosed with nasopharyngeal carcinoma (NPC) in India. NPC is a rare form of head and neck cancer. However, the prognosis of the disease for patients in advanced stages is poor, and India is among the top five countries in the world in terms of disease burden," said M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy's."As the next generation PD-1 inhibitor, Toripalimab has demonstrated superior outcomes for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) versus standard of care, thereby meeting a significant unmet need for patients with NPC in India," he added.
Advertisement
CDSCO Approval for Toripalimab In April, the Central Drugs Standard Control Organisation (CDSCO) granted approval for Dr. Reddy's Laboratories to import and market Toripalimab. The drug will be sold in India under the brand name Zytorvi.Previously, chemotherapy with gemcitabine and cisplatin was the standard treatment for RM-NPC in India. Toripalimab is now approved as a first-line treatment for adults with metastatic or recurrent locally advanced NPC, to be used in combination with gemcitabine and cisplatin.
Global and National Incidence of NPC NPC is a malignant tumor that originates in the epithelium of the nasopharynx. According to GLOBOCAN 2022 data, over 120,000 new cases of NPC were diagnosed globally in 2022. In India, there were 6,519 newly diagnosed NPC cases in the same year, with Kohima in Nagaland reporting an incidence rate of 19.4 per 100,000 population.Global Regulatory Approvals for Toripalimab Toripalimab is the only immuno-oncology drug approved by major regulatory agencies, including the US Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the Medicines and Healthcare Products Regulatory Agency (MHRA), for the treatment of adults with RM-NPC.Reference:
Meta-analysis Links High-risk Epstein-Barr Virus Lineage To Nasopharyngeal Cancer In Southern China
Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have discovered a significant association between specific Epstein-Barr virus (EBV) variants and nasopharyngeal carcinoma (NPC). NPC is a cancer notably prevalent in southern China, where it is 20 times more common than in non-endemic regions of the world. The findings, published in the journal PLoS Pathogens, provide the basis for further scientific research and have potential application to population screening and diagnostic tests.
NPC, often referred to as 'Cantonese Cancer', affects predominantly 30- to 60-year-old men in southern China, including Guangdong and Hong Kong, and Southeast Asia. The cause is associated with various factors, including genetics, environment and viruses. The researchers emphasise that understanding the role of EBV in NPC's pathogenesis is crucial since the virus has 100% association with this cancer.
Background
EBV has long been known to be closely associated with the development of NPC. However, recent research by principal investigators at HKUMed and Sun Yat-sen University Cancer Centre has shown that certain EBV variants might elevate the risk of individuals developing NPC, which is typically diagnosed at a late stage of the disease. Early detection will significantly improve the survival rate and reduce the long-term side effects of treatment, underscoring the importance of ongoing research and public awareness of the factors contributing to NPC.
Research results and significance
A HKUMed research team conducted a meta-analysis of genome-wide association studies (GWAS) of two datasets from Hong Kong and one dataset from Guangdong province, comprising a total of 279 and 227 EBV genomic sequences derived from NPC patients and healthy population carriers in Hong Kong and southern China, respectively. The study revealed high-risk EBV haplotype present in about 70% of NPC cases, compared to about 30% of population carriers. The use of nine genetic markers associated with a high-risk EBV lineage might help predict the presence of NPC, thus providing a potential new avenue for NPC screening and diagnosis.
Professor Alan Chiang Kwok Shing, the study's principal investigator, from the Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, HKUMed, stated that the identification of a distinct high-risk EBV lineage offers valuable insight for future studies of disease mechanisms and the development of targeted screening and diagnostic tests of NPC in endemic regions, such as Hong Kong and southern China, ultimately improving patient outcomes.
"By analysing extensive datasets surveyed in southern China, we confirmed the association of specific genetic variants near the EBER2 region of the EBV genome with NPC. These high-risk variants are tightly linked and form a broader risk haplotype," added Professor Chiang.
About the research team
The study was led by Professor Alan Chiang Kwok Shing and co-investigator Professor Yang Wanling, both from the Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, HKUMed. The key research team members are Dr Wong Ka-wo and Dr Hui Kwai-fung. Other collaborating researchers are Professor Dora Kwong Lai-wan and Professor Maria Lung Li, both from the Department of Clinical Oncology, School of Clinical Medicine, HKUMed.
Acknowledgements
The study was funded by the Health and Medical Research Fund of the Health Bureau, HKSAR government, and received support from the NPC Tissue Bank, under the Research Grants Council Areas of Excellence (AoE) Scheme, which provided additional NPC samples.
Comments
Post a Comment